Introduction

Pt-based chemotherapy
The platinum-based antineoplastic family of chemotherapeutics (colloquially termed platins) are used extensively as firstline treatment for solid tumours. Over 50% (Johnstone et al., 2014) of cancer treatment globally comprises, at least in part, one or more of the four platinum-based drugs approved for medical use in humans.
One such drug is ci s-[PtCl 2 (NH 3 ) 2 ], or cisplatin. Although this compound had been synthesized as early as 1845 under the moniker of Peyrone's salt, the anti-cancer potential of cisplatin was not realized until 1965, in Rosenburg's fortuitous experiments on the influence of current on cell division of Escherichia coli (Rosenberg et al., 1965) . The unexpected changes observed to the shape of the E . coli cells were at first thought to originate from the influence of the electric field on cellular division. However, several additional years of investigation revealed that the culprit was, in fact, the platinum(IV) complex ci s-[PtCl 2 (NH 3 ) 2 ], only present in the experiment at all due to the serendipitous combination of ammonium chloride buffer solution with the platinum electrodes. Subsequent research into the effects of platinum complexes on cells led swiftly to the idea that such compounds could be used as chemotherapeutic agents, and to the subsequent development of the first platinum-based chemotherapeutic, cisplatin.
Cisplatin is used to treat solid tumours of the bladder, cervix and lung, amongst other cancers. It is especially effective against testicular cancer, and is responsible for raising the cure rate from 5% when the drug was first approved, to over 90% today Einhorn (2002) .
A newer member of the platin family is oxalato(trans-l-1,2-cyclohexanediamine)Pt(II), or oxaliplatin, borne from the need for chemotherapeutics to treat cisplatin-resistant cancers (including both intrinsically resistant tumours, and those which acquire resistance over multiple courses of chemotherapy), and to reduce the extensive toxic side effects experienced by patients (Alcindor & Beauger, 2011) . Oxaliplatin is particularly effective against colorectal tumours, against which cisplatin has no activity.
Both cisplatin and oxaliplatin share similar structures, as shown in Figure 1 . Both have square-planar Pt(II) centre, with the primary difference between the two being in the replacement of the monodentate chloride groups in cisplatin with bidentate oxalate in oxaliplatin.
Annular dark-field scanning transmission electron microscopy
In the scanning transmission electron microscope (STEM), a convergent electron beam is rastered across a specimen, and the transmitted signal collected in a number of different imaging modes. The power of STEM comes from the combination of available resolution, and the versatility of the instrument for combination of imaging with various spectroscopic techniques. With the advent of aberration-correction optics, the modern STEM is routinely capable of producing sub-Å resolution.
The annular dark-field (ADF) detector is used in STEM to collect relatively high angles of electron scattering. An annular detector is used, and the total intensity scattered to the detector plotted as a function of probe position to form an image. The ADF STEM imaging mode has two key attributes (Nellist & Pennycook, 2000) . First, the use of high angle scattering, which predominantly occurs through scattering with the atom nuclei in the sample, provides a strongly atomic number sensitive image, with the scattered intensities following an approximately Z 1.7 dependence (Krivanek et al., 2010) . This atomic number dependence allows the Pt to be readily distinguished from the other, lighter elements in the complexes. Second, the image can be described as being incoherent, which means that the total scattered intensity is relatively simply related to the number of atoms present, and allows atom counting to be performed (Van Aert et al., 2013; Varambhia et al., 2016) . In this way, zeptogram-scale weighing of small clusters in the sample is possible.
Due to the powerful combination of both high sensitivity and ease of image interpretability, ADF STEM has found great popularity in the physical sciences as a technique for examining broad ranges of inorganic materials. However, while the STEM was developed with the potential to address biological problems in mind, the technique has thus far gained relatively little purchase in the biological and soft matter fields. This is largely due to challenges associated with sample preparation and electron beam damage when compared with the heavier materials typically examined in materials science (Colliex & Mory, 1994) . Nevertheless, ADF and other STEM techniques present an intriguing prospect for addressing some highly significant biological questions (Leapman, 2004; Pan et al., 2009) .
Although Pt catalysts and nanoparticles have been imaged and quantified extensively using ADF STEM, few attempts have been made to apply such techniques to drugs. The Ptbased nature of the platins means they are especially suitable candidates for the first investigations of pharmaceutical compounds with ADF STEM.
Experimental methods
Sample preparation
Clinical formulations of 1 mg mL −1 cisplatin and 5 mg mL
oxaliplatin infusion solutions (both Accord Healthcare Ltd, Harrow, UK) were prepared for STEM investigation. The vehicle of the cisplatin solution is a mixture of sodium chloride, sodium hydroxide, hydrochloric acid and water, and the oxaliplatin solution excipients are water and lactose monohydrate. Samples were prepared by depositing 3 µL droplets directly onto lacey carbon support film on 300 mesh copper support grids (TAAB Laboratories Equipment Ltd, Aldermaston, UK). The grids were allowed to rest for 120 s, before being dried using the capillary mechanism of filter paper to remove excess drug suspension.
STEM methods
ADF STEM experiments were performed using a JEOL ARM-200F microscope, operated at 200 kV. The microscope is equipped with probe correction for aberrations up to third order. The ADF STEM images presented were obtained using a probe semiconvergence angle of 22.48 mrad.
Results
Cisplatin
ADF STEM images of cisplatin are shown in Figure 2 . At lower magnifications, large self-supported patches of dried drug vehicle are visible, and additional smaller regions are also observed directly on the carbon support. In both cases, increased magnification reveals that the bright regions contain large quantities of metallic nanoparticles, as shown in Figure 2 (B). The nanoparticle size distribution is narrow, with the average diameter being 1.84 nm and most particles falling within ±0.2 nm of this measurement. The structure seen in Figure 3 shows clearly the [110] facecentred cubic structure typical of Pt. Measurement of the lattice spacing yields a value of 3.98 ± 0.15Å, consistent with the spacing for bulk crystalline Pt of 3.91Å (Davey, 1925) .
Other regions within the sample display evidence of very different gross large-scale morphology, as shown in Figure 4 (A), attributable to different local drying conditions. Nevertheless, metallic nanoparticles of ∼1.8 nm average diameter are again observed. The density of nanoparticles in this region is considerably higher than in the structures seen in Figure 2 . However, that the average diameter remains with the bounds of the measurement error indicates that metallic nanoparticles do not arise from the drying of the drug vehicle. Working with the dried clinical formulation of cisplatin is an accepted standard for performing X-ray diffraction (Batista de Carvalho et al., 2011; Singh et al., 2012) and neutron scattering experiments (Batista de Carvalho et al., 2011) .
Another possibility for the origin of such nanoparticles is beam-induced effects. It is likely that the complex would be damaged during electron irradiation, subsequently freeing the Pt to nucleate and grow into nanoparticles. Such a mechanism has been observed in other systems (Sepulveda-Guzman et al., (Jones et al., 2015) ). The different morphology seen in (A) compared to Figure 1(A) is attributed to local differences in drying conditions. (B) shows that despite these differences, Pt nanoparticles of the same sizes are contained in this region. 2007), where continued exposure drives further growth and 'ripening' of the clusters.
In order to address whether the presence of Pt nanoparticles within the cisplatin was indeed a beam-induced effect, multiframe acquisition was performed. The total dose was approximately 3.6 × 10 4 electrons/Å 2 , distributed across a 20-image stack, yielding a dose per frame of 1.8 × 10 3 electrons/Å 2 . Frames from resulting image stack are shown in Figure 5 . No ripening was observed during this process. It would seem rather unexpected that the electron exposure experienced during the first frame of imaging caused damage that would immediately result in Pt nanoparticles with a very narrow size distribution, and furthermore that there would be no evidence for further damage or nanoparticle growth during multiframe acquisition. Nonetheless, electron-beam damage must be always be borne in mind when designing and interpreting data from the electron microscope. Figures 2-4 were recorded using both smaller total electron dose and with a lower dose rate, suggesting that the metallic nanoparticles observed do not result from the effect of the beam.
Oxaliplatin
Identical sample preparation methods to those employed for the cisplatin solution were used to produce oxaliplatin samples, but result in very different observations. As shown in Figure 6 , the latter drug displays significantly more amorphous gross morphology, likely explained by the difference in solution excipients. High-magnification images Figure 6 (B) reveal noncrystalline clusters of Pt atoms of average diameter 1.18 nm, with many single Pt atoms also visible.
Cluster weighing.
As mentioned previously, the power of ADF STEM is that the resultant images are quantitative in nature; that is, the image intensity is directly proportional to the number of atoms in that sample region. To estimate the number of Pt atoms per small cluster, images of the type shown in Figure 6 (B) were analysed using weighing techniques.
In order to calculate the intensity contributed to the image by a single atom, it was necessary to reduce the effects of surrounding light materials and noise on platinum quantification. This was achieved by background subtraction, with the value of the background being obtained by masking the platinum clusters and obtaining the mean intensity of the remaining image. This value was then subtracted from the complete, unmasked, image. The intensity 'weight' of a single atom was then calculated by manually selecting several individual Pt atoms far from clusters and averaging, in order to produce a representative measurement across the frame. The clusters were then remasked, with very close neighbours being distinguished through use of appropriate watershed transforms (Meyer, 1994) . For the purposes of our analysis, clusters not wholly within the frame were excluded. The integrated intensity of each cluster was computed by summing intensities of all pixels within the background-subtracted image, and comparing with the calculated mean intensity of a single atom, to give the number of atoms per cluster N.
As the Pt clusters within the oxaliplatin are irregular in shape, simple measurement in one dimension did not accurately represent cluster size. The area, in pixels, of each cluster was redistributed into a circular arrangement, with the 'equivalent diameter' d taken as an indication of cluster size averaged in 2D. The relationship between atoms per cluster and d is shown in Figure 7 .
For a crystalline Pt nanoparticle, N would be expected to grow with particle diameter cubed:
with the prefactor arising from considerations of Pt lattice spacing and unit cell structure, and for d in units of nanometre. Fitting a similar power law relation to the clusters observed in oxaliplatin fails to replicate this, with N growing instead as
This indicates that the clusters are, in fact, closer to twodimensional rather than 3D, presumably having wetted the supporting carbon film and thus appearing flattened, as observed previously in catalytic ruthenium (Varambhia et al., 2016) .
The detector angles in this study were 54.1 and 276.7 mrad. Consideration of multiple scattering was not necessary for this sample because of its noncrystalline nature. The atoms in the clusters are individually resolved, so scattering from one atom cannot be then scattered by another in the cluster, an effect that was also seen in Varambhia et al (2016) . As free Pt atoms are thermodynamically driven to reduce their energy through crystallization, the fact that the Pt clusters within oxaliplatin Fig. 7 . Number of Pt atoms plotted against cluster size in oxaliplatin. The red curve shows the theoretical relationship for spherical metallic platinum nanoparticles, whereas the blue curve shows the experimentally fitted curve, N = 36.06d 2.37 .
are not instead observed as nanoparticles (as in the case of cisplatin) is indicative that some barrier to metallic particle formation exists within oxaliplatin.
Discussion
Observations of nanoparticles within cisplatin have been reported previously in the literature while examining the functionalization of single-walled carbon nanotubes as drugdelivery devices (Bhirde et al., 2009) . The recorded sizes of between 1 and 2 nm, quantified with reference to nanogold containing a known number of Au atoms, are consistent with those found from the experiments detailed in this article. The higher spatial resolution used in this study suggests that these were also likely metallic in nature. Their observation under such different local environments lends credence to the presence of Pt nanoparticles in the pristine drug rather than being an artefact of the sample preparation methods. No such observations at atomic resolution have been made elsewhere for clinically formulated oxaliplatin.
The anti-cancer properties of both cisplatin and oxaliplatin arise from an origin common to all platins. The primary action mechanism is the induction of cytotoxicity via damage to the tumour deoxyribonucleic acid (DNA). In the case of cisplatin, chlorine leaving groups are displaced by water inside the cell cytoplasm. The aqueated form of the drug preferentially binds to guanine bases in the DNA, and allows for the formation of crosslinks, which interrupt mitosis and ultimately lead to cell death. Oxaliplatin induces cytotoxic effects again via aquation reactions of the oxalate leaving groups, and subsequent binding to DNA, although the exact nature of the cross-linkage is not as clear as in the case of cisplatin (Alcindor & Beauger, 2011) .
That the general mechanism of action is similar for both belies the observed behaviour of cisplatin and oxaliplatin at the nanoscale with ADF. Our results suggest that all the non-Pt species in the cisplatin have been stripped to enable metallic nanoparticle formation, whereas the oxaliplatin is either intact or at least sufficiently intact to prevent metal formation. The consistency of size of the nanoparticles observed in the cisplatin sample independent of the vehicle drying conditions or of the electron exposure suggests that the nanoparticles may be present prior to drying and therefore are either present during drug synthesis or can form spontaneously in the vehicle solution. Even if the drying and observation process has caused the nanoparticle formation, our work suggests that the cisplatin molecule is more susceptible to damage than oxaliplatin, which may have implications for fate of the molecule in vivo.
Although all members of the platinum-based chemotherapeutic family induce unwanted secondary effects in cancer patients, typical side effects differ in both nature and severity. Peripheral neurotoxicity is associated with cisplatin treatment in as many as 50% of cases (Van Der Hoop et al., 1990) , and almost all patients develop some degree of hearing loss due to the ototoxic effects of treatment (McWhinney et al., 2009 ).
The causal mechanisms by which such neurotoxicities arises are unclear. However, efforts to elucidate these pathways have thus far been based upon the understanding that the drug molecules remain intact until entering the cancerous cell. The evidence presented here suggests that this may, in fact, not be the case as the observation of clusters and platinum nanoparticles may demonstrate changes within the clinical formulation of the drugs before they are ever given to patients. However, as the investigations here have been limited in scope to the examination of the pure drug only, we are unable to hypothesize about any physiological consequences which may result if this were true.
In addition, nanoparticles and nano-sized structures are themselves often toxic in their own right, being easily able to cross-cellular membranes and accumulate in body tissues. Investigations of Pt nanoparticle toxicity have proved that platinum is no exception to this rule (Asharani et al., 2010) . Curiously, it has also been suggested that Pt nanoparticles may themselves exhibit an anti-cancer effect .
Ambiguity in the origin of the structural differences observed between these platins suggests that further work is required to more fully understand the role nanoparticles play within these drugs, particularly in vivo. Some such work has already been attempted with the use of nanoscale secondary ion mass spectrometry (NanoSIMS) on cisplatin (Legin et al., 2016) , but such approaches lack the resolution to observe single platinum atoms and nanoparticles as small as those seen in the clinically formulated drug. Through direct imaging of cisplatin and oxaliplatin within tissue, some mechanisms by which these drugs damage both cancer cells and the patient may begin to be more fully understood.
Conclusion
Two widely used members of the platinum-based chemotherapeutic family, cisplatin and oxaliplatin, have been investigated using ADF STEM. Cisplatin has been revealed to contain metallic platinum nanoparticles of approximately 1.8 nm diameter, potentially attributable to the loss of the organic components of the drug structure. In contrast, despite sharing structural similarities with cisplatin, the antineoplastic oxaliplatin has been shown to form nonmetallic clusters, with no evidence of crystallization within the drug. The investigation presented here demonstrates the potential for application of aberrationcorrected STEM on metal-containing pharmaceuticals. Furthermore, the observation of structural change at an atomic level in such compounds suggests interesting prospects for the examination of the physiological consequences in vivo. grant (EP/K040375/1) and DTP studentship (AAS), and a Physiological Society Research Grant 2015 awarded to SJLF.
